ReviewProgress in neurobiology2014
Towards translational therapies for multiple system atrophy.
Review in Progress in neurobiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Pooled it
- Mesenchymal stromal cells in age-related neurodegenerative disorders: mechanisms, translational barriers, and precision strategies.Frontiers in immunology · 2026Review
- Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Consequences of variability in α-synuclein fibril structure on strain biology.Acta neuropathologica · 2022Review
- OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease.NPJ Regenerative medicine · 2022Article
- Identification of cyclin D1 as a major modulator of 3-nitropropionic acid-induced striatal neurodegeneration.Neurobiology of disease · 2022Article
- Evidence of distinct α-synuclein strains underlying disease heterogeneity.Acta neuropathologica · 2021Review
- Identification of a pre-possible multiple system atrophy phase.Acta neurologica Scandinavica · 2021Article
- Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis.BMC neuroscience · 2018Article
- The neuropathology of multiple system atrophy and its therapeutic implications.Autonomic neuroscience : basic & clinical · 2018Review
- Synucleinopathies: common features and hippocampal manifestations.Cellular and molecular life sciences : CMLS · 2017Review
- The Diagnosis and Natural History of Multiple System Atrophy, Cerebellar Type.Cerebellum (London, England) · 2016Article
- α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.Acta neuropathologica · 2016Article
- Multiple system atrophy: pathogenic mechanisms and biomarkers.Journal of neural transmission (Vienna, Austria : 1996) · 2016Review
- Review: Multiple system atrophy: emerging targets for interventional therapies.Neuropathology and applied neurobiology · 2016Review
- Glia and alpha-synuclein in neurodegeneration: A complex interaction.Neurobiology of disease · 2016Review
- Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy.Frontiers in neuroscience · 2016Article
- Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.BMC neuroscience · 2015Article
- Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.Neurotoxicity research · 2015Article
- Natural history of multiple system atrophy in the USA: a prospective cohort study.The Lancet. Neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Multiple system atrophy (MSA) is a fatal adult-onset neurodegenerative disorder of uncertain etiopathogenesis manifesting with autonomic failure, parkinsonism, and ataxia in any combination. The underlying neuropathology affects central autonomic, striatonigral and olivopontocerebellar pathways and it is associated with distinctive glial cytoplasmic inclusions (GCIs, Papp-Lantos bodies) that contain aggregates of α-synuclein. Current treatment options are very limited and mainly focused on symptomatic relief, whereas disease modifying options are lacking. Despite extensive testing, no neuroprotective drug treatment has been identified up to now; however, a neurorestorative approach utilizing autologous mesenchymal stem cells has shown remarkable beneficial effects in the cerebellar variant of MSA. Here, we review the progress made over the last decade in defining pathogenic targets in MSA and summarize insights gained from candidate disease-modifying interventions that have utilized a variety of well-established preclinical MSA models. We also discuss the current limitations that our field faces and suggest solutions for possible approaches in cause-directed therapies of MSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.